Sage Group News

Sage Represents BioHit Healthcare: Opportunity for Leadership in Nicotine-Free Smoking Cessation Usi

BioHit Healthcare has developed and gained approval in Europe for the Acetium® lozenge. This binds cigarette smoke-derived acetaldehyde in the saliva, thus reducing the known effects of acetaldehyde in maintaining smoking dependence. Regular use of the Acetium® lozenge during smoking increased the likelihood of smoking cessation 1.5-fold compared with placebo. Acetium® lozenge is CE mark approved and may be sold in some countries as a food supplement. Acetium® lozenge works by slowly releasing L-cysteine (a natural amino acid) into saliva. L-cysteine binds up to 90 % of cigarette smoke-derived acetaldehyde. The lozenge also contains xylitol, which improves oral health. Poor oral hygiene inc